These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 17386879

  • 21. Hyperkalemia risk and treatment of heart failure.
    Segura J, Ruilope LM.
    Heart Fail Clin; 2008 Oct; 4(4):455-64. PubMed ID: 18760757
    [Abstract] [Full Text] [Related]

  • 22. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: Future research needs prioritization.
    Crowley MJ, Powers BJ, Myers ER, McBroom AJ, Sanders GD.
    Am Heart J; 2012 May; 163(5):777-782.e8. PubMed ID: 22607854
    [Abstract] [Full Text] [Related]

  • 23. Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure.
    Harjola VP, Follath F, Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Hochadel M, Komajda M, Lopez-Sendon JL, Ponikowski P, Tavazzi L.
    Eur J Heart Fail; 2010 Mar; 12(3):239-48. PubMed ID: 20156940
    [Abstract] [Full Text] [Related]

  • 24. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.
    Jneid H, Moukarbel GV, Dawson B, Hajjar RJ, Francis GS.
    Am J Med; 2007 Dec; 120(12):1090.e1-8. PubMed ID: 18060931
    [Abstract] [Full Text] [Related]

  • 25. Effect of combination angiotensin-converting enzyme and angiotensin receptor blocker therapy on heart failure mortality and morbidity.
    Kapoor JR.
    Am J Cardiol; 2008 Mar 01; 101(5):744-5. PubMed ID: 18308033
    [No Abstract] [Full Text] [Related]

  • 26. Medical agents acting on the renin-angiotensin-aldosterone axis for the treatment of heart failure.
    Kawano H, Node K.
    Hypertens Res; 2010 Mar 01; 33(3):192-3. PubMed ID: 20203682
    [No Abstract] [Full Text] [Related]

  • 27. [Combination of ACEI and ARB therapy for heart failure].
    Nishikimi T, Matsuoka H.
    Nihon Rinsho; 2007 May 28; 65 Suppl 5():140-4. PubMed ID: 17569311
    [No Abstract] [Full Text] [Related]

  • 28. Initial therapy of hypertension.
    Obstet Gynecol; 2005 May 28; 105(5 Pt 1):1140-2. PubMed ID: 15863559
    [No Abstract] [Full Text] [Related]

  • 29. Now or never: optimal antihypertensive therapy in the elderly.
    Prisant LM.
    Prev Cardiol; 2008 May 28; 11(4):201-9. PubMed ID: 19476572
    [Abstract] [Full Text] [Related]

  • 30. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P.
    J Hypertens; 2008 Jul 28; 26(7):1282-9. PubMed ID: 18550998
    [Abstract] [Full Text] [Related]

  • 31. [Angiotensin converting enzyme inhibitors in arterial hypertension and cardiac failure. The question of the dose].
    González-Juanatey JR.
    Med Clin (Barc); 2000 Jul 28; 114 Suppl 2():24-7. PubMed ID: 10916802
    [Abstract] [Full Text] [Related]

  • 32. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK, Duval S, Manske C, Vazquez G, Barber C, Miller L, Luepker RV.
    Am Heart J; 2007 Jun 28; 153(6):1064-73. PubMed ID: 17540211
    [Abstract] [Full Text] [Related]

  • 33. [Pharmacologic treatment of heart failure in the elderly].
    Erdmann E.
    Dtsch Med Wochenschr; 2013 Apr 28; 138(14):700-2. PubMed ID: 23533033
    [No Abstract] [Full Text] [Related]

  • 34. All clinical trials are not created equal: The dilemma of HEAAL.
    Hauptman PJ.
    Eur J Heart Fail; 2008 Sep 28; 10(9):817-8. PubMed ID: 18774334
    [No Abstract] [Full Text] [Related]

  • 35. Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be?
    Hollenberg NK, Epstein M.
    Clin J Am Soc Nephrol; 2006 Sep 28; 1(5):1046-8. PubMed ID: 17699325
    [No Abstract] [Full Text] [Related]

  • 36. Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease.
    Ripley E.
    Am Heart J; 2009 Jun 28; 157(6 Suppl):S7-S16. PubMed ID: 19450722
    [Abstract] [Full Text] [Related]

  • 37. Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or both in chronic heart failure.
    Young JB.
    Heart Fail Clin; 2005 Apr 28; 1(1):39-47. PubMed ID: 17386832
    [No Abstract] [Full Text] [Related]

  • 38. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ.
    Prev Cardiol; 2008 Apr 28; 11(4):215-22. PubMed ID: 19476574
    [Abstract] [Full Text] [Related]

  • 39. Antihypertensive medications for risk reduction of first and recurrent ischemic stroke.
    Padma V, Fisher M, Moonis M.
    Expert Rev Cardiovasc Ther; 2004 Nov 28; 2(6):867-76. PubMed ID: 15500432
    [Abstract] [Full Text] [Related]

  • 40. The importance of managing cardiovascular risk in the treatment of hypertension: the role of ACE inhibitors and ARBs.
    Pierson CA, Epstein BJ, Roberts ME.
    J Am Acad Nurse Pract; 2008 Nov 28; 20(11):529-38. PubMed ID: 19128336
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.